Retatrutide

Retatrutide (Inj)

Retatrutide is an investigational incretin-based peptide engineered as a triple agonist of GLP-1, GIP, and glucagon receptors. It has been studied in clinical trials for obesity and metabolic disease, with reported effects on body weight, glycemic control, and cardiometabolic risk markers.

Dosing Protocols

— 5 mg Vial —

Reconstitute: Add 1.0 mL bacteriostatic water → ~5.0 mg/mL concentration.
Typical weekly range: 2–8 mg once weekly (gradual escalation over 8–12 weeks).
Easy measuring: At 5.0 mg/mL, 1 unit = 0.01 mL ≈ 50 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C for up to 4 weeks.

Schedule: Weekly subcutaneous injections for 12–48 weeks.
Cycle Length: Minimum 24 weeks; trials extended to 48 weeks.
Goal: Support significant weight reduction and metabolic improvements through triple-receptor activation.

Frequency: Inject once weekly subcutaneously. For doses >5 mg, reconstitute multiple vials. Volumes >1.0 mL may be split into 2 separate subcutaneous injections at different sites.

Phase	Dose	Syringe (U-100)
Weeks 1–4	2 mg	40 units (0.40 mL)
Weeks 5–8	4 mg	80 units (0.80 mL)
Weeks 9–12	6 mg	120 units (1.20 mL)
Weeks 13+	8 mg	160 units (1.60 mL)

— 10 mg Vial —

Reconstitute: Add 1.0 mL bacteriostatic water → ~10.0 mg/mL concentration.
Typical weekly range: 2–8 mg once weekly (gradual escalation over 8–12 weeks).
Easy measuring: At 10.0 mg/mL, 1 unit = 0.01 mL ≈ 100 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C for up to 4 weeks.

Schedule: Weekly subcutaneous injections for 12–48 weeks.
Cycle Length: Minimum 24 weeks; trials extended to 48 weeks.
Goal: Support significant weight reduction and metabolic improvements through triple-receptor activation.

Frequency: Inject once weekly subcutaneously. All doses ≤10 mg can be drawn from one reconstituted 10 mg vial. Volumes >1.0 mL may be split into 2 separate subcutaneous injections at different sites.

Phase	Dose	Syringe (U-100)
Weeks 1–4	2 mg	20 units (0.20 mL)
Weeks 5–8	4 mg	40 units (0.40 mL)
Weeks 9–12	6 mg	60 units (0.60 mL)
Weeks 13+	8 mg	80 units (0.80 mL)

— 20 mg Vial —

Reconstitute: Add 2.0 mL bacteriostatic water → ~10.0 mg/mL concentration.
Typical weekly range: 2–8 mg once weekly (gradual escalation over 8–12 weeks).
Easy measuring: At 10.0 mg/mL, 1 unit = 0.01 mL ≈ 100 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C for up to 4 weeks.

Schedule: Weekly subcutaneous injections for 12–48 weeks.
Cycle Length: Minimum 24 weeks; trials extended to 48 weeks.
Goal: Support significant weight reduction and metabolic improvements through triple-receptor activation.

Frequency: Inject once weekly subcutaneously. All doses ≤12 mg can be drawn from one reconstituted 20 mg vial. Volumes >1.0 mL may be split into 2 separate injections.

Phase	Dose	Syringe (U-100)
Weeks 1–4	2 mg	20 units (0.20 mL)
Weeks 5–8	4 mg	40 units (0.40 mL)
Weeks 9–12	6 mg	60 units (0.60 mL)
Weeks 13+	8 mg	80 units (0.80 mL)

— 30 mg Vial —

Reconstitute: Add 3.0 mL bacteriostatic water → ~10.0 mg/mL concentration.
Typical weekly range: 2–8 mg once weekly (gradual escalation over 8–12 weeks).
Easy measuring: At 10.0 mg/mL, 1 unit = 0.01 mL ≈ 100 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C for up to 4 weeks.

Schedule: Weekly subcutaneous injections for 12–48 weeks.
Cycle Length: Minimum 24 weeks; trials extended to 48 weeks.
Goal: Support significant weight reduction and metabolic improvements through triple-receptor activation.

Frequency: Inject once weekly subcutaneously. All doses ≤12 mg can be drawn from one reconstituted 30 mg vial. Volumes >1.0 mL may be split into 2 separate injections.

Phase	Dose	Syringe (U-100)
Weeks 1–4	2 mg	20 units (0.20 mL)
Weeks 5–8	4 mg	40 units (0.40 mL)
Weeks 9–12	6 mg	60 units (0.60 mL)
Weeks 13+	8 mg	80 units (0.80 mL)

Benefits

• Significant body-weight reduction reported in clinical trial settings (dose-dependent).
• Improved glycemic control markers (fasting glucose, HbA1c) in clinical research.
• Reductions in waist circumference and improvements in cardiometabolic risk markers in trials.
• Potential increases in energy expenditure via glucagon receptor agonism (mechanistic rationale).

Mechanism of Action

Retatrutide activates GLP-1 and GIP receptors (enhancing glucose-dependent insulin secretion, slowing gastric emptying, and reducing appetite) while also activating the glucagon receptor, which can increase energy expenditure. The combined incretin + glucagon signaling is designed to drive greater weight loss than GLP-1-only agonism.

Side Effects

Potential adverse effects reported in literature and/or anecdotally include:

• Nausea, vomiting, diarrhea, constipation.
• Decreased appetite.
• GERD-like symptoms.
• Injection-site reactions.
• Possible gallbladder events with rapid weight loss (class-associated).
• Potential pancreatitis risk signals (class-associated; causality debated).

Side Effect Management

• Titrate slowly; most GI effects are dose-escalation related.
• Prioritize hydration and electrolytes if GI upset occurs.
• Smaller/lower-fat meals can reduce nausea.
• Pause escalation or reduce dose if persistent GI symptoms occur.
• Monitor for severe abdominal pain in clinical contexts.

Contraindications

• Personal/family history of medullary thyroid carcinoma or MEN2 (GLP-1 class boxed warning).
• History of pancreatitis (use caution).
• Severe gastroparesis or significant GI motility disorders.
• Pregnancy or breastfeeding.

Research Citations

PubMed-linked citations for verification. Many studies are preclinical (animal/in-vitro).

1. Triple–hormone receptor agonist retatrutide for obesity: a randomized clinical trial. N Engl J Med. 2023. PMID: 37318111 (doi: 10.1056/NEJMoa2301972)
2. Coagonism/triple agonism at GLP-1, GIP, and glucagon receptors for obesity: biology and pharmacology (review). Nat Rev Endocrinol. PubMed
3. Glucagon receptor agonism and energy expenditure: mechanisms relevant to multi-agonist therapies. Endocr Rev. 2018. PubMed

---